title: Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].
abstract: We report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor. This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells. The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.
authors.affiliation: Department of Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
authors.forename: Ju-Hee
authors.initials: JH
authors.lastname: Lee
authors.affiliation: Department of Chemistry, Columbia University, New York, NY 10027.
authors.forename: Yuanshan
authors.initials: Y
authors.lastname: Yao
authors.affiliation: Department of Chemistry, Columbia University, New York, NY 10027.
authors.forename: Adaickapillai
authors.initials: A
authors.lastname: Mahendran
authors.affiliation: Department of Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
authors.forename: Lang
authors.initials: L
authors.lastname: Ngo
authors.affiliation: Department of Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
authors.forename: Gisela
authors.initials: G
authors.lastname: Venta-Perez
authors.affiliation: Department of Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
authors.forename: Megan L
authors.initials: ML
authors.lastname: Choy
authors.affiliation: Department of Chemistry, Columbia University, New York, NY 10027 rb33@columbia.edu marksp@mskcc.org.
authors.forename: Ronald
authors.initials: R
authors.lastname: Breslow
authors.affiliation: Department of Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065; rb33@columbia.edu marksp@mskcc.org.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Marks
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry; D044482:Benzeneacetamides / Q000737:chemistry* / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D000073864:Histone Deacetylase 6; D056572:Histone Deacetylase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry; D006655:Histone Deacetylases / Q000235:genetics*; D006877:Hydroxamic Acids / Q000737:chemistry* / Q000494:pharmacology*; D051379:Mice; D015394:Molecular Structure; D017239:Paclitaxel; D014404:Tubulin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D044482:Benzeneacetamides; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C000604168:N-hydroxy-4-((N-(2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide; D014404:Tubulin; C499033:Hdac6 protein, mouse; D000073864:Histone Deacetylase 6; D006655:Histone Deacetylases; D017239:Paclitaxel
keywords: HDAC; cancer; tubulin